Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Strategies that interfere with the binding of the receptor programmed cell death protein-1 (PD-1) to programmed death ligand-1 (PD-L1) have shown marked efficacy against many advanced cancers, including those that are negative for PD-L1. Precisely why patients with PD-L1 negative tumors respond to P...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaslavsky, Alexander B., Adams, M. P., Cao, X., Maj, T., Choi, J. E., Stangl-Kremser, J., Patel, S., Putelo, A., Lee, S. K., Nallandhighal, S., Kasputis, A., Alva, A., Lew, M., Qin, A., Mehra, R., Morgan, T. M., Salami, S. S., Reichert, Z., Udager, A., Zou, W., Palapattu, Ganesh S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652857/
https://www.ncbi.nlm.nih.gov/pubmed/33168847
http://dx.doi.org/10.1038/s41598-020-76351-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652857/
https://www.ncbi.nlm.nih.gov/pubmed/33168847
http://dx.doi.org/10.1038/s41598-020-76351-4

Ejemplares similares